{"id":"NCT04183790","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older","officialTitle":"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of ELX/TEZ/IVA Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-17","primaryCompletion":"2024-02-24","completion":"2024-02-24","firstPosted":"2019-12-03","resultsPosted":"2025-05-18","lastUpdate":"2025-05-18"},"enrollment":64,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"The study evaluates the long-term safety, tolerability, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in participants with cystic fibrosis (CF).","primaryOutcome":{"measure":"Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"From Baseline up to Week 196","effectByArm":[{"arm":"ELX/TEZ/IVA","deltaMin":64,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":21,"countries":["United States","Australia","Canada","Ireland","United Kingdom"]},"refs":{"pmids":["40454869","37983082","37154609","33331662"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":64},"commonTop":["Cough","Pyrexia","Headache","Oropharyngeal pain","Nasal congestion"]}}